| Primary |
| Rheumatoid Arthritis |
30.2% |
| Systemic Lupus Erythematosus |
22.2% |
| Drug Use For Unknown Indication |
11.2% |
| Product Used For Unknown Indication |
9.8% |
| Cutaneous Lupus Erythematosus |
3.3% |
| Juvenile Arthritis |
2.5% |
| Arthritis |
2.3% |
| Whipple's Disease |
2.2% |
| Lupus Nephritis |
2.0% |
| Arthralgia |
1.9% |
| Drug Therapy |
1.7% |
| Mixed Connective Tissue Disease |
1.7% |
| Angioedema |
1.6% |
| Autoimmune Disorder |
1.2% |
| Suicide Attempt |
1.2% |
| Adjuvant Therapy |
1.1% |
| Pain |
1.1% |
| Immunosuppression |
0.9% |
| Sjogren's Syndrome |
0.9% |
| Type 2 Diabetes Mellitus |
0.9% |
|
| Pneumonia Legionella |
8.3% |
| Refractory Anaemia |
8.3% |
| Rash |
7.6% |
| Vomiting |
7.6% |
| Hypoglycaemia |
5.6% |
| Nausea |
5.6% |
| Histoplasmosis |
4.9% |
| Urticaria |
4.9% |
| Vision Blurred |
4.9% |
| Weight Decreased |
4.9% |
| Weight Increased |
4.9% |
| Cardiac Arrest |
4.2% |
| Meningitis Aseptic |
4.2% |
| Abdominal Pain |
3.5% |
| Dyspnoea |
3.5% |
| Headache |
3.5% |
| Malaise |
3.5% |
| Product Substitution Issue |
3.5% |
| Rash Generalised |
3.5% |
| Toxicity To Various Agents |
3.5% |
|
| Secondary |
| Product Used For Unknown Indication |
38.9% |
| Rheumatoid Arthritis |
19.4% |
| Systemic Lupus Erythematosus |
12.3% |
| Drug Use For Unknown Indication |
7.7% |
| Drug Therapy |
4.3% |
| Adjuvant Therapy |
2.7% |
| Whipple's Disease |
1.6% |
| Dermatomyositis |
1.5% |
| Hypertension |
1.4% |
| Osteoporosis |
1.3% |
| Autoimmune Hepatitis |
1.1% |
| Psoriatic Arthropathy |
1.1% |
| Lupus Nephritis |
0.9% |
| Pain |
0.9% |
| Angioedema |
0.9% |
| Asthma |
0.8% |
| Prophylaxis |
0.8% |
| Foetal Exposure During Pregnancy |
0.8% |
| Juvenile Arthritis |
0.8% |
| Drug Exposure During Pregnancy |
0.7% |
|
| Completed Suicide |
21.8% |
| Galactorrhoea |
11.5% |
| Teratogenicity |
5.1% |
| Cellulitis |
4.5% |
| Drug Exposure During Pregnancy |
4.5% |
| Fatigue |
4.5% |
| Maternal Drugs Affecting Foetus |
4.5% |
| Meningitis |
4.5% |
| Angioedema |
3.8% |
| Diarrhoea |
3.8% |
| Renal Failure Acute |
3.8% |
| Retinal Tear |
3.8% |
| Hepatitis Toxic |
3.2% |
| Nausea |
3.2% |
| Posterior Reversible Encephalopathy Syndrome |
3.2% |
| Small Cell Lung Cancer Stage Unspecified |
3.2% |
| Vomiting |
3.2% |
| Abortion Induced |
2.6% |
| Contusion |
2.6% |
| Herpes Zoster |
2.6% |
|
| Concomitant |
| Rheumatoid Arthritis |
35.2% |
| Drug Use For Unknown Indication |
22.3% |
| Product Used For Unknown Indication |
19.9% |
| Systemic Lupus Erythematosus |
3.2% |
| Pain |
3.2% |
| Hypertension |
2.7% |
| Osteoporosis |
2.1% |
| Arthritis |
1.6% |
| Depression |
1.5% |
| Vitamin Supplementation |
1.2% |
| Prophylaxis |
1.0% |
| Asthma |
0.8% |
| Gastrooesophageal Reflux Disease |
0.7% |
| Psoriatic Arthropathy |
0.7% |
| Diabetes Mellitus |
0.7% |
| Hypothyroidism |
0.7% |
| Anxiety |
0.7% |
| Hypersensitivity |
0.6% |
| Insomnia |
0.6% |
| Arthralgia |
0.5% |
|
| Injection Site Pain |
13.0% |
| Rheumatoid Arthritis |
12.7% |
| Vomiting |
8.9% |
| Weight Decreased |
7.0% |
| Pneumonia |
5.1% |
| Incorrect Dose Administered |
4.6% |
| Drug Ineffective |
4.5% |
| Sinusitis |
4.5% |
| Urinary Tract Infection |
4.3% |
| Pain In Extremity |
3.8% |
| Systemic Lupus Erythematosus |
3.5% |
| Death |
3.3% |
| Headache |
3.3% |
| Injection Site Swelling |
3.1% |
| Nasopharyngitis |
3.1% |
| Pain |
3.1% |
| Arthralgia |
3.0% |
| Injection Site Warmth |
3.0% |
| Weight Increased |
3.0% |
| Wrong Technique In Drug Usage Process |
3.0% |
|
| Interacting |
| Rheumatoid Arthritis |
23.5% |
| Systemic Lupus Erythematosus |
23.5% |
| Drug Use For Unknown Indication |
17.6% |
| Electrocardiogram Abnormal |
5.9% |
| Smoking Cessation Therapy |
5.9% |
| Autoimmune Disorder |
2.9% |
| Blood Phosphorus Abnormal |
2.9% |
| Contraception |
2.9% |
| Hypokalaemia |
2.9% |
| Hypotension |
2.9% |
| Overdose |
2.9% |
| Product Used For Unknown Indication |
2.9% |
| Tuberculosis |
2.9% |
|
| Systemic Lupus Erythematosus |
22.2% |
| Drug Interaction |
11.1% |
| Drug Resistance |
11.1% |
| Hepatic Cirrhosis |
11.1% |
| Injection Site Atrophy |
11.1% |
| Portal Hypertension |
11.1% |
| Skin Lesion |
11.1% |
| Thrombocytopenia |
11.1% |
|
